3io Therapeutics

3io Therapeutics is a Toronto-based biotechnology company focused on the development and commercialisation of the next generation of viral immunotherapies for cancer. 3io is currently developing a novel viral immunotherapy based on bovine herpesvirus type 1 (BHV-1), a virus that naturally infects cattle but is non-pathogenic in humans. 3io is committed to accelerating its development as a new therapeutic platform to improve treatment responses and outcomes for hard-to-treat cancers, including those with KRAS-mutations.